PHARMACOKINETIC INTERACTION BETWEEN IVACAFTOR AND LUMACAFTOR IN CYSTIC FIBROSIS PATIENTS

被引：0
|
作者：
Hanafin, P. [2 ]
Rao, G. [2 ]
Schneider-Futschik, E. [1 ]
机构：
[1] Univ Melbourne, Melbourne, Vic, Australia
[2] UNC Eshelman Sch Pharm, Chapel Hill, NC USA
来源：
RESPIROLOGY | 2020年 / 25卷
基金：
英国医学研究理事会;
关键词：
D O I：
暂无
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
TO 070
引用
收藏
页码：58 / 58
页数：1
相关论文
共 50 条
  • [21] Safety and efficacy of treatment with lumacaftor in combination with ivacaftor in younger patients with cystic fibrosis
    Cheng, Pi Chun
    Alexiou, Stamatia
    Rubenstein, Ronald C.
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2019, 13 (05) : 417 - 423
  • [22] Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects
    Kuk, Kelly
    Taylor-Cousar, Jennifer L.
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2015, 9 (06) : 313 - 326
  • [23] Lumacaftor/ivacaftor therapy is associated with reduced hepatic steatosis in cystic fibrosis patients
    Kutney, Katherine
    Donnola, Shannon B.
    Flask, Chris A.
    Gubitosi-Klug, Rose
    O'Riordan, MaryAnn
    McBennett, Kimberly
    Sferra, Thomas J.
    Kaminski, Beth
    WORLD JOURNAL OF HEPATOLOGY, 2019, 11 (12) : 761 - 772
  • [24] Lumacaftor/ivacaftor therapy is associated with reduced hepatic steatosis in cystic fibrosis patients
    Katherine Kutney
    Shannon B Donnola
    Chris A Flask
    Rose Gubitosi-Klug
    MaryAnn O'Riordan
    Kimberly McBennett
    Thomas J Sferra
    Beth Kaminski
    World Journal of Hepatology, 2019, 11 (12) : 761 - 772
  • [25] An Observational Study of Outcomes and Tolerances in Patients with Cystic Fibrosis Initiated on Lumacaftor/Ivacaftor
    Jennings, Mark T.
    Dezube, Rebecca
    Paranjape, Shruti
    West, Natalie E.
    Hong, Gina
    Braun, Andrew
    Grant, Jonathan
    Merlo, Christian A.
    Lechtzin, Noah
    ANNALS OF THE AMERICAN THORACIC SOCIETY, 2017, 14 (11) : 1662 - 1666
  • [26] Compassionate Use of Lumacaftor/Ivacaftor in Cystic Fibrosis: Spanish Experience
    Diab-Caceres, Layla
    Maria Giron-Moreno, Rosa
    Teresa Pastor-Sanz, Maria
    Quintana-Gallego, Esther
    Delgado-Pecellin, Isabel
    Blanco-Aparicio, Marina
    Maiz, Luis
    Maria Garcia-Clemente, Marta
    Luna-Paredes, Carmen
    Mondejar-Lopez, Pedro
    Ruiz-de-Valbuena, Marta
    Fernandez, Ofelia
    Barrio, Maribel
    Gonzalez, Maribel
    Lopez-Neyra, Alejandro
    Cols-i-Roig, Maria
    Palou-Rotger, Alexandre
    Javier Gomez-de-Terreros-Caro, Francisco
    ARCHIVOS DE BRONCONEUMOLOGIA, 2018, 54 (12): : 614 - 618
  • [27] Factors Predisposing the Response to Lumacaftor/Ivacaftor in People with Cystic Fibrosis
    Mesinele, Julie
    Ruffin, Manon
    Guillot, Loic
    Boelle, Pierre-Yves
    Corvol, Harriet
    French CF Modifier Gene Study Investigators
    JOURNAL OF PERSONALIZED MEDICINE, 2022, 12 (02):
  • [28] Reduced Intestinal Inflammation With Lumacaftor/Ivacaftor in Adolescents With Cystic Fibrosis
    Tetard, Candice
    Mittaine, Marie
    Bui, Stephanie
    Beaufils, Fabien
    Maumus, Pascale
    Fayon, Michael
    Burgel, Pierre-Regis
    Lamireau, Thierry
    Delhaes, Laurence
    Mas, Emmanuel
    Enaud, Raphael
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2020, 71 (06): : 778 - 781
  • [29] How Clinically Efficient Are Lumacaftor/Ivacaftor for Cystic Fibrosis Patients: An Updated Literature Review
    Perveen, Sumera
    Chaudhry, Muhammad Reza
    AlBabtain, Sarah
    Amreen, Sana
    Brar, Simrandeep K.
    Zeb, Mehwish
    Khan, Safeera
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (12)
  • [30] Lumacaftor/ Ivacaftor improves exercise tolerance in patients with Cystic Fibrosis and severe airflow obstruction
    Wark, Peter A. B.
    Cookson, Kim
    Thiruchelvam, Theeba
    Brannan, John
    Dorahy, Douglas J.
    BMC PULMONARY MEDICINE, 2019, 19 (1)
12345